OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. Obecure is repurposing betahistine, which is... Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.
- Mechanism
- Curator reviewed
OBE101 is a H1 receptor agonist and partial H3 receptor antagonist. Because inhibition of H1 receptors increases feeding, agonism of H1 receptors by OBE101 should reduce feeding. By also partially antagonizing H3, OBE101 impedes a negative feedback loop that essentially prolongs stimulation of the H1 receptors.
- Primary indication
- Investigated for use/treatment in adverse effects (drug), hyperlipidemia, and obesity.Curator reviewed
- Code names
- OBE101
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with OBE101, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account